Seropositivity against Chlamydia pneumoniae in patients with coronary atherosclerosis

Clinical Cardiology

Volumn 23, Issue 5, 2000, Pages 327-330

  Romeo, Francesco ^d   Martuscelli, Eugenio ^a   Chirieolo, Gaetano ^a   Cerabino, Luigia Maria ^d   Ericson, Katharina ^b   Saldeen, Tom G P ^b   Mehta, Jawahar L ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Chlamydia pneumoniae; Coronary artery disease; Seropositivity

Indexed keywords

ANTIBIOTIC THERAPY; ARTICLE; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; HUMAN; MAJOR CLINICAL STUDY; RISK FACTOR;

EID: 0034054927     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960230504     Document Type: Article

References (32)

1. Mehta JL, Saldeen TGP, Rand K: Interactive role of infection, inflammation, and traditional risk factors in atherosclerosis and coronary artery disease. J Am Coll Cardiol 1998;31:1217-1225
2. Dahlén GH, Boman J, Birgander LS, Lindblom B: Lp(a) lipoprotein, IgG, IgA and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary artery disease. Atherosclerosis 1995;114:165-174
3. Saikku P, Mattila K, Nieminen MS, Huttonen JK, Leinonen MI, Ekman MR, Makela PH, Valtonen V: Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988;2: 983-986
4. Thorn DH, Wang SP, Grayston JT, Siscovick S, Stewart DK, Kronmal RA, Weiss NS: Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease. Arterioscler Thromb 1991;11:547-551
5. Gaydos CA, Summersgill JT, Sahney NN, Ramirez JA, Quinn TC: Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun 1996;64:1614-1620
6. Wyrick PB, Brunridge EA: Growth of Chlamydia psittaci in macrophagis. Infect Immun 1978;19:1054-1060
7. Godzik KL, O'Brien ER, Wang SK, Kuo CC: In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae. J Clin Microbiol 1995;33:2411-2414
8. Muhleslein JB, Anderson JL, Hammond EH, Zhao L, Trehan S, Schwobe EP, Carlquist JF: Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998;97: 633-636
9. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ: Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of acute myocardial infarction. Circulation 1997;96:404-407
10. Gurfunkel E, Bozovich G, Daroca A, Beck E, Mautner B: Randomised trial of roxithromycin in non-Q-wave coronary syndromes. Lancet 1997;350:404-407
11. Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C, Hall S, Brady J, Egger M, Home B, Lim T: Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation 1999;99:1540-1547
12. Altman R, Rouvier J, Scazziota A, Absi RS, Gonzalez C: Lack of association between prior infection with Chlamydia pneumoniae and acute or chronic coronary artery disease. Clin Cordiol 1999; 22:85-90
13. Maass M, Gieffers J, Krause E, Engel PM, Bartels C, Solbach W: Poor correlation between microimmunofluorescence serology and polymerase chain reaction for detection of vascular Chlamydia pneumoniae infection in coronary artery disease patients. Med Microbiol Immunol (Berl) 1998;187:103-106
14. Anderson JL, Carlquist JF, Muhlestein JB, Home BD, Elmer SP: Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction. J Am Coll Cardiol 1998;32:35-41
15. Kark JD, Leinonen M, Paltiel O, Saikku P: Chlamydia pneumoniae and acute myocardial infarction in Jerusalem. Int J Epidemiol 1997;26:730-738
16. Weiss SM, Roblin PM, Gaydos CA, Cummings P, Patton DL, Schulhoff N, Shani J, Frankel R, Penny K, Quinn TC, Hammerschlag MD, Schachter J: Failure to detect Chlamydia pneumoniae in coronary atheromas of patients undergoing atherectomy. J Infect Dis 1996;173:957-962
17. Moazed TC, Kuo C, Grayston JT, Campbell LA: Murine models of Chlamydia pneumoniae infection and atherosclerosis. J Infect Dis 1997;175:883-890
18. Shor A, Kuo CC, Patton DL: Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J 1992;82:158-161
19. Kuo CC, Grayston JT, Campbell LA, Goo YA, Wissler RW, Beneditt EP: Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 year old). Proc NatlAcad Sci USA 1995;92: 6911-6914
20. Campbell LA, O'Brien ER, Cappuccio AL, Kuo C-C, Wang S-P, Stewart D, Grayston JT: Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues. J Infect Dis 1995;172:585-588
21. Ong G, Thomas BJ, Mansfield AO, Davidson BR, Taylor-Robinson D: Detection and widespread distribution of Chlamydia pneumoniae in the vascular system and its possible implications. J Clin Part 1996;49:102-106
22. Muhlestein JB, Hammond EH, Carlquist JF, Radicke E, Thomson MJ, Karnqounis LA, Woods ML, Anderson JL: Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol 1996;27:1555-1561
23. Ramirez JA: Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis: The Chlamydia pneumoniae/Atherosclerosis Study Group. Ann Intern Med 1996;125:979-982
24. Saldeen TGP, Ericsson K, Lindquist O, Pahlson C, Lindblom B, Liu AJ, Mehta JL: Chlamydia and HLA-DR genotypes in coronary atherosclerosis (abstr). J Am Coll Cardiol 1998;31:272A
25. Fryer RH, Schwobe EP, Woods ML, Rodgers GM: Chlamydia species infect human vascular endothelial cells and induce procoagulant activity. J Invest Med 1997;45:168-174
26. Cleeman JI, Lenfant C: National Cholesterol Education Program: Progress and prospects. J Am Med Assoc 1998;280:2099-2104
27. Hajjar DP, Pomerantz KB, Falcone DJ, Weksler BB, Grant AJ: Herpes simplex virus infection in human arterial cells. Implications in atherosclerosis. J Clin Invest 1987;80:1317-1321
28. Hu H, Pierce GN, Zhong G: The atherogenic effects of Chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest 1999;103:747-753
29. Murray LJ, O'Reilly DP, Ong GM, O'Neill C, Evans AE, Bamford KB: Chlamydia pneumoniae antibodies are associated with an atherogenic lipid profile. Heart 1999;81:239-244
30. Laurila A, Bloigu A, Nayha S, Hassi J, Leinonen M, Saikku P: Chronic Chlamydia pneumoniae infection is associated with a serum lipid profile known to be a risk factor for atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:2910-2913
31. Hoffmeister A, Rothebachor D, Wanner P, Boda G, Persson K, Brenner H, Hombach V, Koenig W: Systemic inflammation, serpositivity to Chlamydial lipopolysaceharide and coronary artery disease - a case control study (abstr). Circulation 1998;1-602
32. Ridker PM, Kundin RB, Stampfer MJ, Poulin S, Hennekens CM: A prospective study of Chlamydia pneumoniae IgG serpositivity and risk of future myocardial infarction (abstr). Circulation 1998;1-602